Introduction
============

Vitamin D hydroxylation-deficient rickets type 1A (VDDR1A) (MIM 264700), or pseudo-vitamin D-deficiency rickets type 1, is an autosomal recessively inherited disorder resulting from deficiency of renal 1α-hydroxylase[@B1] and characterized by hypotonia, growth retardation, muscle weakness, severe rickets, hypocalcemia, and secondary hyperparathyroidism[@B2][@B3][@B4]. VDDR1A is an extremely rare disease and the incidence in Denmark is estimated at 0.3/100,000 individuals per year[@B5]. To date, 5 patients with VDDR1A have been reported in Korea[@B6][@B7]. However, it is assumed that there are many unreported or genetically unconfirmed cases. The biochemical hallmark of VDDR1A is normal 25-hydroxyvitamin D3 (25(OH)D~3~) with low 1,25-dihydroxyvitamin D3 (1,25(OH)~2~D~3~) levels[@B8]. Other laboratory findings are characterized by hypocalcemia, hypophosphatemia, and increased serum concentrations of parathyroid hormone (PTH)[@B9].

The *CYP27B1* gene encodes P450c1α, renal and keratinocyte 1α-hydroxylase, and consists of 9 exons spanning 5 kb[@B10][@B11][@B12]. To date, 68 different mutations have been reported worldwide (<http://www.hgmd.org>). Several mutations in the *CYP27B1* gene are more frequently reported in certain ethnic groups[@B2][@B6][@B8]. The disease is more frequent in the French Canadian population of the Saguenay region of Quebec[@B8].

Treatment with active vitamin D (1,25(OH)~2~D~3~ or calcitriol) improves the clinical and biochemical abnormalities[@B13]. We report on a female with VDDR1A, who presented with hypocalcemic seizure at the age of 13 months. We describe the clinical features, molecular characteristics, and clinical course of the patient, with a review of the literatures.

Case report
===========

A 13-month-old female was admitted to the Pediatric Emergency Department due to a generalized tonic-clonic seizure lasting for a few minutes. She was born in the 39th week of gestation without perinatal problems. She could control her head 4 months after birth and rolled over at 5 months. At 7 months, she could sit alone. However, she could not stand or walk until 14 months of age.

Biochemical findings showed a low serum calcium of 4.8 mg/dL (normal range, 8.3--10 mg/dL); phosphorus of 4.3 mg/dL (normal range, 2.5--4.5 mg/dL), and elevated alkaline phosphatase of 1,665 U/L (normal range, \<269 U/L). PTH was 178 pg/mL (normal range, 10--65 pg/mL) and 25(OH) D3 was 75.1 ng/mL. Initial 1,25(OH)2D3 level was 5.26 pg/mL (normal range, 15--90 pg/mL). Echocardiography showed QT prolongation. An evaluation for renal tubular acidosis was normal, with normal urine pH. Tubular reabsorption of phosphate was 88%. Radiographic images of the wrist showed cupping and fraying of the ulna and distal radius, as well as metaphyseal widening, indicating rickets ([Fig. 1A](#F1){ref-type="fig"}). Harrison sulcus and rachitic rosary were also observed ([Fig. 1B](#F1){ref-type="fig"}). There was no family history of rickets.

A mutation analysis of the *CYP27B1* gene was performed at the age of 10 years. All coding exons and intron in flanking regions of *CYP27B1* were amplified by polymerase chain reaction and directly sequenced using an ABI3130x1 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). She was homozygous for c.589+1G\>A in the splice donor site in intron 3 ([Fig. 2](#F2){ref-type="fig"}), which was reported to be pathogenic[@B14].

The patient was immediately treated with intravenous calcium gluconate (20 mg/kg/day) for the hypocalcemic seizure. After her symptoms were relieved, she was discharged with oral calcium carbonate (30 mg/kg/day of elemental calcium) and calcitriol (0.5 µg/day). Compliance with the treatment was good, resulting in rapid amelioration of the clinical, biochemical, and radiological abnormalities. The serum calcium normalized within a month, and there were no recurrent seizures. The cupping and fraying of the ulna and distal radius was improved after 5 months of therapy. After 2 years of treatment with calcitriol and calcium supplement, follow-up radiological images demonstrated fully healing of the long-bone bowing and flaring ([Fig. 1C](#F1){ref-type="fig"}). The patient\'s biochemical parameters and anthropometry during the follow-up period are shown in [Table 1](#T1){ref-type="table"}.

The patient had neither genu valgum/varum nor scoliosis. Nephrocalcinosis did not develop during the follow-up period. But she had severe dental caries. At her last visit at the age of 17.8 years, her height and weight were 166 cm (1.1 standard deviation score \[SDS\]) and 68 kg (1.6 SDS), respectively, and she had no symptoms with the calcitriol (0.5 µg/day) and calcium (400 mg/day of elemental calcium) treatment ([Fig. 3](#F3){ref-type="fig"})

Discussion
==========

This report described long-term clinical course of a patient with VDDR1A, who was confirmed by molecular analysis of the *CYP27B1* gene analysis. A few VDDR1A cases with short-term clinical courses have been reported in Korea[@B6][@B7].

The biologically inactive prohormones, such as vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol) are sequentially hydroxylated in the liver and kidneys by hepatic 25-hydroxylase (CYP2R1) and renal 1α-hydroxylase (CYP27B1), respectively[@B15][@B16]. The active form of vitamin D (1,25(OH)~2~D~3~) plays an important role in calcium homeostasis and bone growth[@B16][@B17][@B18]. Renal synthesis of 1,25(OH)~2~D~3~ from 25OHD~3~ by 1α-hydroxylation is the rate-limiting step in the synthesis of active form of vitamin D[@B16][@B17][@B18]. 1α-hydroxylation is stimulated by PTH and negatively regulated by fibroblast growth factor-23 and 1,25(OH)~2~D~3~ itself[@B6].

The biochemical findings in VDDR1A are characterized by hypocalcemia, hypophosphatemia, and low or undetectable serum levels of 1,25(OH)~2~D~3~ despite high serum levels of PTH and 25(OH)D~3~ [@B9]. The clinical symptoms and signs are similar to hypophosphatemic rickets. However, it is possible to differentiate VDDR1A from hypophosphatemic rickets by low serum concentrations of 1,25(OH)~2~D~3~ and high PTH. Increased PTH and renal excretion of phosphate results in hypophosphatemia[@B9] because PTH reduces phosphate and increases calcium reabsorption from the renal proximal tubules, and also increases serum calcium via osteoclast-mediated bone resorption[@B19]. These mechanisms result in severely elevated serum alkaline phosphatase[@B19].

In the present study, the c.589+1G\>A mutation was identified, which was reported to cause premature stop codon at 63 bp downstream from the end of exon 3[@B14]. G-to-A substitution in the first nucleotide of a splice site is a frequent mutation in numerous genes, resulting in skipping of the exon[@B20]. Deletions, premature terminations due to splice site mutations, and insertions are common defects that disrupt or eliminate the heme-binding domain of CYP27B1 and thereby inactivate this enzyme[@B6].

Calcitriol treatment (10--400 ng/kg/day) results in regression of the symptoms and normalization of laboratory findings, including decreased calcium and phosphorus, and increased alkaline phosphatase and PTH[@B2]. At her most recent visit, the biochemical values were improved to serum calcium of 8.5 mg/dL; phosphorus 3.1 mg/dL, and decreased alkaline phosphatase 90 U/L; PTH was 104 pg/mL. If there are persistently elevated PTH levels after initiation of treatment with calcium supplementation, secondary hyperparathyroidism should be ruled out. Most patients show significant height gains with calcitriol, similar to our case. In cases of growth failure during this treatment, poor adherence to the medication should be considered[@B2]. In conclusion, we report a case of VDDR1A presenting in a patient with hypocalcemic seizure and rickets, in whom a homozygous splicing mutation (c.589+1G\>A) was identified.
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![Radiographic images of the patient with vitamin D hydroxylation-deficient rickets type 1A. (A) Simple X-ray findings show fraying and cupping of the radius, ulnar, tibia and fibula, and metaphyseal widening at presentation. (B) Harrison sulcus and rachitic rosary were also observed (arrow). (C) After 2 years of treatment, marked improvement in widening and flaring of metaphysis of long bone were revealed.](apem-21-169-g001){#F1}

![Mutation analysis of the *CYP27B1* gene. Partial sequences of *CYP21B1* show homozyous splicing mutation in intron 3 (c.589+1G\>A).](apem-21-169-g002){#F2}

![Growth curve of of the patient with vitamin D hydroxylation-deficient rickets type 1A. Mid parental height (arrow).](apem-21-169-g003){#F3}

###### Clinical and laboratory findings of the patient with vitamin D hydroxylation-deficient rickets type 1A

![](apem-21-169-i001)

  -----------------------------------------------------------------------------------------------------------------------------------------
  Age (yr)   Height SDS   Calcium\    Phosphate\   ALP\      25(OH)D~3~(ng/mL)\   1,25(OH)~2~D~3~\   PTH\       Urine calcium/creatinine\
                          (mg/dL)\    (mg/dL)\     (IU/L)\   (30--100)            (pg/mL)\           (pg/mL)\   (mg/mg)\
                          (8.3--10)   (2.5--4.5)   (\<269)                        (15--90)           (10--65)   (\<0.2)
  ---------- ------------ ----------- ------------ --------- -------------------- ------------------ ---------- ---------------------------
  1.1        0.8          4.8         4.3          1,665     75.1                 5.26               178.0      ND

  6.0        --0.39       8.9         4.8          217       ND                   ND                 65.8       ND

  7.4        ND           9.1         5.1          175       ND                   ND                 23.8       ND

  8.0        --0.01       8.6         5.1          204       58.4                 ND                 84.4       ND

  9.6        0.08         8.8         5.0          228       52.4                 54.7               96.6       ND

  13.7       0.85         8.5         4.8          149       13.1                 35.0               97.1       ND

  14.3       1.05         8.3         3.1          115       14.4                 60.3               33.3       ND

  14.5       1.1          8.2         3.5          118       8.9                  32.6               86.0       ND

  14.8       1.1          8.6         3.8          103       13.6                 9.5                78.0       ND

  15.0       1.1          6.8         4.2          167       14.2                 12.5               149.0      ND

  15.3       1.1          7.7         4.7          133       11.2                 9.9                122.0      0.042

  15.5       1.1          8.2         3.4          132       8.1                  25.8               98.4       0.035

  16.0       1.1          8.4         4.3          116       9.5                  30.9               215.0      0.027
  -----------------------------------------------------------------------------------------------------------------------------------------

SDS, standard deviation score; ALP, alkaline phosphatase; 25(OH)D~3~, 25-hydroxyvitamin D3; 1,25(OH)~2~D~3~, 1,25-dihydroxyvitamin D3; PTH, parathyroid hormone; ND, not done.
